The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jin Won Kim
No Relationships to Disclose
 
Hongjae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; Celgene Cancer Care Links/BMS; Eisai; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Eisai; Menarini; Sanofi; SERVIER
Research Funding - Dong-A ST; Roche
 
Choong-kun Lee
No Relationships to Disclose
 
Ji-Won Kim
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Hye Jin Choi
No Relationships to Disclose
 
Se Jun Park
No Relationships to Disclose
 
Jeesun Yoon
No Relationships to Disclose
 
Myung Ah Lee
No Relationships to Disclose